Mumbai-based biopharmaceutical company Bharat Serums and Vaccines (BSV) has entered into an exclusive distribution agreement with MediWound, a fully integrated biopharmaceutical company in Israel focused on next-generation biotherapeutic solutions for tissue repair and regeneration, for exclusive marketing and distribution of NexoBrid in India. 

NexoBrid, a new paradigm in treatment of severe burns, is a concentrate of proteolytic enzymes enriched in bromelain, and an easy to use, topically applied product that removes eschar in four hours without harming the surrounding healthy tissues. 

Speaking on this, Vishwanath Swarup, COO- Domestic Operations, BSV, said “Burn treatment and management continues to remain a public health challenge in India. According to the National Health Portal of India, as many as 70 lakh burn injuries are reported with mortality rate as high as 1.4 lakh per year, with almost 91,000 of these being women. As a leading player in the women’s health segment, it is our endeavour to widen access to NexoBrid in India in order to save and improve lives of several women in the country.”

Ofer Gonen, Chief Executive Officer of MediWound said, “NexoBrid is now approved and selling in 42 countries worldwide, and we see steady growth in the markets where it is available. Approval in India represents a significant opportunity for us.  With a high incidence of burns in India, we believe that NexoBrid can offer a safer treatment towards burn management.  We also look forward to our PDUFA date of January 1, 2023 and the potential NexoBrid launch in the US during the second half of 2023 with our commercial partner, Vericel.”